Alnylam Pharmaceuticals Inc (ALNY)vsEffector Therapeutics Inc (EFTR)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
EFTR
Effector Therapeutics Inc
$0.00
0.00%
HEALTHCARE · Cap: $940
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 550113% more annual revenue ($3.71B vs $675,000). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
EFTR
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for EFTR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Reasonable price relative to book value
Revenue surging 117.0% year-over-year
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : EFTR
The strongest argument for EFTR centers on Price/Book, Revenue Growth. Revenue growth of 117.0% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : EFTR
The primary concerns for EFTR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
EFTR carries more volatility with a beta of 0.96 — expect wider price swings.
EFTR is growing revenue faster at 117.0% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 34/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Effector Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through the selective modulation of RNA translation. By specifically altering protein synthesis within tumor cells, the company is addressing critical unmet needs in oncology with its innovative small molecule treatments. With a robust and diverse pipeline of candidates under development, Effector Therapeutics is dedicated to advancing precision medicine, ultimately striving to improve treatment outcomes and quality of life for cancer patients in an evolving biotechnology landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?